

1 Co-development of gut microbial metabolism and visual neural circuitry over human 2 infancy

3 Kevin S. Bonham^{1*}, Emma T. Margolis^{2*}, Guilherme Fatur Bottino², Ana Sobrino², Fadheela Patel³, Shelley McCann¹, Michal R.
4 Zieff⁴, Marlie Miles⁴, Donna Herr⁴, Lauren Davel⁴, Cara Bosco², Khula South Africa Data Collection Team[†], Curtis Huttenhower⁵
5 Nicolò Pini^{6,7}, Daniel C. Alexander⁸, Derek K. Jones⁹, Steve C. R. Williams¹⁰, Dima Amso¹¹, Melissa Gladstone¹², William P. Fifer^{6,7},
6 Kirsten A. Donald^{3,13}, Laurel J. Gabard-Durnam^{2‡}, Vanja Klepac-Ceraj[‡],

7 *These authors contributed equally

8 † Khula South African Data Collection Team: Layla Bradford, Simone Williams, Lauren Davel, Tembeka Mhlakwaphalwa, Bokang
9 Methola, Khanyisa Nkubungu, Candice Knipe, Zamazimba Madi, Nwabisa Mlandu

10 ‡ co-corresponding authors

11 ¹Department of Biological Sciences, Wellesley College, Wellesley, MA, USA

12 ²Department of Psychology, Northeastern University, Boston, MA, USA

13 ³Division of Medical Microbiology, University of Cape Town, Cape Town, Western Cape, ZAF

14 ⁴Department of Paediatrics and Child Health, University of Cape Town, Cape Town, Western Cape, ZAF

15 ⁵Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, USA

16 ⁶Department of Psychiatry, Columbia University, Irving Medical Center, New York City, NY, USA

17 ⁷Division of Developmental Neuroscience, New York State Psychiatric Institute, New York City, NY, USA

18 ⁸Centre for Medical Image Computing, Department of Computer Science, University College London, London, United Kingdom

19 ⁹Cardiff University Brain Research Imaging Centre, Cardiff University, Cardiff, Wales, United Kingdom

20 ¹⁰Department of Neuroimaging, King's College London, United Kingdom

21 ¹¹Department of Psychology, Columbia University, New York City, NY, USA

22 ¹²Department of Women and Children's Health, Institute of Life Course and Medical Science, Alder Hey Children's NHS Foundation
23 Trust, University of Liverpool, Liverpool, United Kingdom

24 ¹³Neuroscience Institute, University of Cape Town, Cape Town, Western Cape, ZAF

25 **Running title:** Infant gut microbiome and visual neurodevelopment

26 **Keywords:** visual cortex development, metagenome, infant gut microbiome, visual-evoked potential, neuroplasticity

27 **ORCID numbers:**

28 Kevin S. Bonham	0000-0003-3200-7533	Emma T. Margolis	0000-0002-2036-8078
29 Guilherme Fatur Bottino	0000-0003-1953-1576	Ana Sobrino	
30 Fadheela Patel	0000-0001-5177-7416	Michal Zieff	0000-0001-9352-9947
31 Lauren Davel		Cara Bosco	
32 Curtis Huttenhower	0000-0002-1110-0096	Nicolò Pini	0000-0002-0839-6033
33 Daniel C. Alexander	0000-0003-2439-350X	Derek K. Jones	0000-0003-4409-8049
34 Steve C. R. Williams	0000-0003-4299-1941	Dima Amso	0000-0001-6798-4698
35 Melissa Gladstone	0000-0002-2579-9301	William P. Fifer	0000-0002-6936-9303
36 Shelley McCann	0000-0002-9753-7968	Kirsten A. Donald	0000-0002-0276-9660
37 Laurel J. Gabard-Durnam	0000-0002-4564-8068	Vanja Klepac-Ceraj	0000-0001-5387-5706

38 **Abstract**

39 Infancy is a time of elevated neuroplasticity supporting rapid brain and sensory development. The gut
40 microbiome, also undergoing extensive developmental changes in early life, may influence brain
41 development through metabolism of neuroactive compounds. Here, we leverage longitudinal data from
42 194 infants across the first 18 months of life to show that microbial genes encoding enzymes play a key
43 role in modulating early neuroplasticity are associated with visual cortical neurodevelopment, measured
44 by the Visual-Evoked Potential (VEP). Neuroactive compounds included neurotransmitters GABA and
45 glutamate, the amino acid tryptophan, and short-chain fatty acids involved in myelination, including
46 acetate and butyrate. Microbial gene sets around 4 months of age were strongly associated with the VEP
47 from around 9 to 14 months of age and showed more associations than concurrently measured gene
48 sets, suggesting microbial metabolism in early life may affect subsequent neural plasticity and
49 development.

50 **Introduction**

51 The gut microbiome in early life has potential long-term implications for brain and body health. One
52 important way this influence can occur is through interactions with the central nervous system as a
53 “microbial-gut-brain axis” (1–3) The metabolic potential of the microorganisms that inhabit the gut vastly
54 exceeds that of human cells alone, with microbial genes outnumbering host genes by a hundredfold (4)
55 In particular, gut microbes have the ability to metabolize and synthesize many neuroactive compounds
56 (5). However, the physiological relevance of this in humans has been difficult to quantify, particularly
57 during initial neurological development in early life.

58 Extensive work in preclinical models suggests that these neuroactive compounds can influence the brain
59 through both direct and indirect pathways. For example, major neurotransmitters (e.g., glutamate, γ -
60 aminobutyric acid (GABA), serotonin, and dopamine) are readily synthesized and degraded by intestinal
61 microbes and can enter circulation and pass the blood-brain barrier to influence central nervous function
62 (6–9) Glutamatergic/GABA-ergic signaling is critical for balancing the brain's excitatory and inhibitory
63 neurotransmission levels, and alterations in the bi-directional glutamatergic/GABA-ergic signaling
64 between the gut microbiome and brain are implicated in several physical and mental health conditions
65 (10,11). Similarly, the gut and the microbiome are critical to the regulation of metabolism for the
66 neurotransmitters serotonin and dopamine, particularly through the metabolism of dietary tryptophan
67 (12). Moreover, short-chain fatty acids (SCFAs) produced by the gut microbiome may impact the brain
68 directly by modulating neurotrophic factors, glial and microglial maturation and myelination, and
69 neuroinflammation (13,14). Other indirect pathways for gut microbial influence on the brain include vagus
70 nerve stimulation, neuroendocrine modulation and immune system regulation (1).

71 Rapidly growing literature connects the metabolic potential of the gut microbiome and brain function in
72 humans (reviewed in 7,15,16), but the overwhelming majority of this research is conducted in cohorts of
73 adult participants. Importantly, both the gut microbiome and the brain undergo dramatic and rapid
74 development over the first postnatal years (17–19) However, very little is currently known about how gut-
75 brain influences emerge or change during this critical window (20–22). Interrogating this early co-
76 development in humans is, therefore, key to both understanding adaptive gut-brain function and behavior
77 and to informing strategies to support it. Specifically, the visual cortex has been shown to be sensitive to
78 gut microbiome modulations in adults (23) and in rodents (24), yet the visual cortex undergoes its most
79 rapid period of plasticity and maturation over infancy at the same time the microbiome changes most
80 significantly (25–27). Visual cortical functional maturation can be robustly indexed via
81 electroencephalography (EEG) with the Visual-Evoked Potential (VEP) response to visual stimuli from
82 birth. The VEP is especially useful for indexing visual neurodevelopment as its morphology includes
83 amplitude deflections as well as latencies to those deflections reflecting maturation of function and
84 structure, respectively.

85 Here, we investigated the longitudinal co-development of microbial metabolic potential quantified via
86 genes encoding enzymes that metabolize neuroactive compounds and visual neurodevelopment as
87 indexed by the VEP in a longitudinal community sample of 194 infants from Gugulethu in Cape Town,
88 South Africa, recruited as part of the prospective longitudinal “Khula” Study (28). Stool samples and EEG
89 were each collected at up to 3 visits in the first 18 months of life. Shotgun metagenomic sequencing was
90 used to obtain microbial gene sequences from infant stool samples. To index visual cortical functional
91 development, latencies and peak amplitudes were extracted from each component of the VEP (i.e., first
92 negative-going deflection, N1; first positive-going deflection, P1; and second negative-going deflection,
93 N2), producing six VEP features of interest. We evaluated the concurrent association between microbial
94 genes and VEP amplitudes and latencies, and we tested prospective influences of microbial genes from
95 early visits on VEP changes at later visits. In this way, we were able to reveal the temporal dynamics of
96 gut-brain co-development within individuals during this most critical window of plasticity in both systems.

97 **Methods and Materials**

98 **Cohort**

99 **Participants and Study Design**

100 Infants were recruited from local community clinics in Gugulethu, an informal settlement in Cape Town,
101 South Africa, as part of a prospective longitudinal study (most enrollments happened prenatally with 16%
102 of infants enrolled shortly after birth; 28). The first language for the majority of residents in this area is
103 Xhosa. Study procedures were offered in English or Xhosa depending on the language preference of the
104 mother. This study was approved by the relevant university Health Research Ethics Committees
105 (University of Cape Town study number: 666/2021). Informed consent was collected from mothers on
106 behalf of themselves and their infants. Demographic information, including maternal place of birth, primary
107 spoken language, maternal age at enrollment, maternal educational attainment, and maternal income,
108 were collected at enrollment (see Table 1).

109 Families were invited to participate in three in-lab study visits over their infant’s first two years of life. At
110 the first in-lab study visit (hereafter visit-1), occurring when infants were between approximately 2 months
111 and 6 months of age, the following data were collected: the infants’ age (in months), sex, infant
112 electroencephalography (EEG), and infant stool samples.

113 At the second study visit (hereafter visit-2), occurring when infants were between approximately 6 months
114 and 12 months of age (age in months: $M=8.60$, $SD=1.48$, $range=5.41-12.00$) and at the third study visit
115 (hereafter visit-3), occurring when infants were between approximately 12 months and 17 months of age
116 (age in months: $M=14.10$, $SD=1.04$, $range=12.10-17.00$), infant EEG and stool samples were collected
117 again. At visits in which infants were unable to complete both EEG and stool samples on the same day,
118 EEG and stool samples were collected on different days. For concurrent time point analyses, infants with
119 EEG and stool collected more than two months apart were excluded. Not all infants had EEG and
120 microbiome data collected at all three time points or contributed usable data at all three-time points.

121 All enrolled infants received a comprehensive medical exam at each visit, which included assessments of
122 eye-related conditions. Several infants ($n=3$) were identified as having eye-related anomalies during the
123 medical exam, and they were excluded from any further analyses.

124 **EEG Processing**

125 **EEG Data Acquisition**

126 Electroencephalography (EEG) data were acquired from infants while they were seated in their
127 caregiver’s lap in a dimly-lit, quiet room using a 128-channel high density HydroCel Geodesic Sensor Net
128 (EGI, Eugene, OR), amplified with a NetAmps 400 high-input amplifier, and recorded via an Electrical

129 Geodesics, Inc. (EGI, Eugene, OR) system with a 1000 Hz sampling rate. EEG data were online
130 referenced to the vertex (channel Cz) through the EGI Netstation software. Impedances were kept below
131 100K Ω in accordance with the impedance capabilities of the high-impedance amplifiers. Geodesic
132 Sensor Nets with modified tall pedestals designed for improving inclusion of infants with thick/curly/tall
133 hair were used as needed across participants (29). Shea moisture leave-in castor oil conditioner was
134 applied to hair across the scalp prior to net placement to improve both impedances and participant
135 comfort (29). This leave-in conditioner contains insulating ingredients, so there is no risk of electrical
136 bridging, and has not been found to disrupt the EEG signal during testing (unpublished data).
137 Conditioning hair in this way allows for nets to lay closer to the scalp for curly/coily hair types and makes
138 for more comfortable net removal at the end of testing.

139 The Visual-Evoked Potential (VEP) task was presented using Eprime 3.0 software (Psychology Software
140 Tools, Pittsburgh, PA) on a Lenovo desktop computer with an external monitor 19.5 inches on the
141 diagonal facing the infant (with monitor approximately 65 cm away from the infant). A standard phase-
142 reversal VEP was induced with a black and white checkerboard (1cm x 1 cm squares within the board)
143 stimulus that alternated presentation (black squares became white, white squares became black) every
144 500 milliseconds for a total of 100 trials. Participant looking was monitored by video and by an assistant
145 throughout data collection. If the participant looked away during the VEP task, the task was rerun.

146 **EEG Data Pre-Processing**

147 VEP data were exported from native Netstation .mff format to .raw format and then pre-processed using
148 the HAPPE+ER pipeline within the HAPPE v3.3 software, an automated open-source EEG processing
149 software validated for infant data (30). A subset of the 128 channels were selected for pre-processing that
150 excluded the rim electrodes as these are typically artifact-laden (channels excluded from pre-processing
151 included in Table S4). The HAPPE pre-processing pipeline was run with user-selected specifications
152 outlined in Table S4.

153 Pre-processed VEP data were considered usable and moved forward to VEP extraction if HAPPE pre-
154 processing ran successfully, at least 15 trials were retained following bad trial rejection, and at least one
155 good channel was kept within the visual ROI. Note that channels marked bad during pre-processing had
156 their data interpolated as part of standard preprocessing pipelines for ERPs (30). Interpolated channels
157 were included in analyses here as is typically done in developmental samples, and given the low overall
158 rates of interpolation present (e.g., an average of between 4 to 5 of 5 possible good channels in the
159 region of interest were retained at each visit time point).

160 **Visual-Evoked Potentials (VEPs)**

161 VEP waveforms were extracted and quantified using the HAPPE+ER v3.3 GenerateERPs script (30).
162 Electrodes in the occipital region were selected as a region of interest (i.e., E70, E71, E75, E76, E83).
163 The VEP waveform has three main components to be quantified: a negative N1 peak, a positive P1 peak,
164 and a negative N2 peak. Due to normative maturation of the waveforms as infants age, one set of user-
165 specified windows for calculating component features was used for visit-1 and 2 and another was used
166 for visit-3. For visits 1 and 2, the window for calculating features for the N1 component was 40-100 ms,
167 75-175 ms for the P1 component, and 100-325 ms for the N2 component. For visit-3, the window for
168 calculating features for the N1 component was 35-80 ms, 75-130 ms for the P1 component, and 100-275
169 ms for the N2 component. HAPPE+ER parameters used in extracting the ERPs are summarized in Table
170 S5.

171 To correct for the potential influence of earlier components on later components, corrected amplitudes
172 and latencies were calculated and used in all analyses. Specifically, the P1 amplitude was corrected for
173 the N1 amplitude (corrected P1 amplitude = P1 - N1 amplitude), the P1 latency was corrected for the N1
174 latency (corrected P1 latency = P1 - N1 latency), the N2 amplitude was corrected for the P1 amplitude

175 (corrected N2 amplitude = N2 - P1 amplitude), and the N2 latency was corrected for the P1 latency
176 (corrected N2 latency = N2 - P1 latency).

177 All VEPs were visually inspected to ensure that the automatically extracted values were correct and were
178 adjusted if observable peaks occurred outside the automated window bounds. Participants were
179 considered to have failed this visual inspection and were subsequently removed from the data set if their
180 VEP did not produce three discernible peaks. VEP waveforms of included participants by time point are
181 included in Figure 1E. 97 infants provided usable VEP data at visit-1, 130 infants provided usable VEP
182 data at visit-2, and 131 infants provided usable VEP data at visit-3. For included participants, EEG data
183 quality metrics are summarized in Table S6. T-tests for data quality metrics (i.e., number of trials
184 collected, number of trials retained, number of channels retained in the ROI, Pearson's r for data pre- vs.
185 post-wavelet thresholding at 5, 8, 12, and 20 Hz) were run between each visit combination (i.e., visit-1 vs.
186 visit-2, visit-1 vs. visit-3, visit-2 vs. visit-3). For visits that differed in data quality, follow-up post hoc
187 correlations were run for the data quality measure with each VEP feature at each visit in the T-test. In no
188 case did the data quality metric relate to VEP features at multiple visits, making it highly unlikely the data
189 quality difference contributed to results.

190 **Biospecimens and sequencing**

191 **Sample Collection**

192 Stool samples (n=315) were collected in the clinic by the research assistant directly from the diaper,
193 transferred to Zymo DNA/RNA Shield™ Fecal collection Tubes (#R1101, Zymo Research Corp., Irvine,
194 USA) and immediately frozen at -80 °C. Stool samples were not collected if the participant had taken
195 antibiotics within the two weeks prior to sampling.

196 **DNA Extraction**

197 DNA extraction was performed at Medical Microbiology, University of Cape Town, South Africa, from stool
198 samples collected in DNA/RNA Shield™ Fecal collection tube using the Zymo Research Fecal DNA
199 MiniPrep kit (# D4300, Zymo Research Corp., Irvine, USA) following manufacturer's protocol. To assess
200 the extraction process's quality, ZymoBIOMICS® Microbial Community Standards (#D6300 and #D6310,
201 Zymo Research Corp., Irvine, USA) were incorporated and subjected to the identical process as the stool
202 samples. The DNA yield and purity were determined using the NanoDrop® ND -1000 (Nanodrop
203 Technologies Inc. Wilmington, USA).

204 **Sequencing**

205 Shotgun metagenomic sequencing was performed on all samples at the Integrated Microbiome Research
206 Resource (IMR, Dalhousie University, NS, Canada). A pooled library (max 96 samples per run) was
207 prepared using the Illumina Nextera Flex Kit for MiSeq and NextSeq from 1 ng of each sample. Samples
208 were then pooled onto a plate and sequenced on the Illumina NextSeq 2000 platform using 150+150 bp
209 paired-end P3 cells, generating 24M million raw reads and 3.6 Gb of sequence per sample (31).

210 **Statistics / computational analysis**

211 **Age-Related Changes in VEP Features**

212 To determine age-related changes in VEP features, six linear mixed models with each VEP feature as the
213 outcome (i.e., N1 amplitude/latency, P1 amplitude/latency, N2 amplitude/latency) were run using the lme4
214 package (32) in R with age in months as the predictor of interest and number of retained trials as a
215 covariate.

216 **Metagenome processing**

217 Raw metagenomic sequence reads ($2.5 \times 10^7 \pm 1.4 \times 10^7$ reads/sample) were processed using tools
218 from the bioBakery as previously described (17,33). Briefly, KneadData v0.10.0 was used with default
219 parameters to trim low-quality reads and remove human sequences (using reference database hg37).
220 Next, MetaPhlan v3.1.0 (using database mpa_v31_CHOCOPHlan_201901) was used with default
221 parameters to map microbial marker genes to generate taxonomic profiles. Taxonomic profiles and raw
222 reads were passed to HUMAnN v3.7 to generate stratified functional profiles.

223 **Microbial community analysis**

224 Principal coordinates analysis was performed in the julia programming language (34) using the
225 Microbiome.jl package (35). Bray-Curtis dissimilarity (Distances.jl) was calculated across all pairs of
226 samples, filtering for species-level classification. Classical multidimensional scaling was performed on the
227 dissimilarity matrix (MultivariateStats.jl), and axes with negative eigenvalues were discarded.

228 **Feature Set Enrichment Analysis (FSEA)**

229 Potentially neuroactive genesets were extracted from Supplementary Dataset 1 from (5). Gut-brain
230 modules provide Kegg Orthologue IDs (KOs) (36,37), which were mapped to UniRef90 IDs using the
231 utility mapping file provided with HUMAnN v3.1 (33). For each stool/VEP pair, logistic regression (LR)
232 was performed, linking the presence or absence of that UniRef in a sample with each VEP feature (i.e.,
233 N1, P1, and N2 latencies and amplitudes), controlling for the age at which the stool sample was
234 collected, the number of retained VEP trials, and the difference in age between the stool collection and
235 VEP measurement. For concurrently collected stool and VEP comparisons (Figure 2), participants whose
236 stool collection and VEP measurements were more than two months apart were excluded.

237
$$\text{UniRef} \sim \text{vep} + \text{age_months} + \text{n_trials} + \text{age_diff}$$

238 FSEA was performed on each geneset that had at least five members in each comparison group
239 according to the procedure set out in Subramanian et. al. (2005) (38). Briefly, enrichment scores (ES) are
240 calculated based on the rank order of z-statistics from the LR for each UniRef. A permutation test was
241 then performed where the ES for 5000 random samples of ranks of the same length as the gene set are
242 calculated, and the pseudo-p value is the fraction of permutations where the permutation ES has a
243 greater absolute value than the true ES.

244 Benjamini-Hochberg FDR correction was performed separately on all concurrently tested geneset/VEP
245 feature combinations and all longitudinal geneset/VEP feature combinations. Corrected p-values (q-
246 values) less than 0.2 were considered statistically significant.

247 For longitudinal comparisons, all participants that had a stool sample collected at one visit and a VEP
248 assessment at a subsequent visit were included (visit-1 stool \rightarrow visit-2 VEP, $N = 84$; $v1 \rightarrow v2$, $N = 76$; $v2$
249 $\rightarrow v3$, $N = 69$). A total of 95 geneset/VEP features were significant when using an FDR-corrected p-value
250 cutoff of $q < 0.2$. To ensure the robustness of these findings, we randomly permuted participant IDs
251 between the stool and VEP assessments and repeated the analysis. Over 10 random permutations, a
252 mean of 19.5 significant associations were identified, suggesting that FDR correction is correctly
253 calibrating the false-positive rate.

254 **Data and code availability**

255 Code for initial processing of data and for analyses performed in this manuscript are available on github
256 and archived on Zenodo (39). Input data will be archived on Dryad and downloadable via included scripts
257 in analysis code upon publication.

258 Results

259 The brain and microbiome develop rapidly in the first months of life

260 To investigate the co-development of the gut microbiome and visual neurodevelopment, we collected
261 stool and the VEP in a longitudinal cohort of 194 children in South Africa during the first 18 months of life
262 (Figure 1A, B, Table 1; visit-1, N = 119, age 3.6 ± 0.7 months, visit-2, N = 144, age 8.7 ± 1.4 months,
263 visit-3, N = 130, age 14.2 ± 1.0 months). As expected for children at this age (40–42), microbial
264 composition was developmentally dependent, with the first principal coordinate axis for both taxonomic
265 profiles (Figure 1C; variance explained = 15.1%; $R = -0.50$) and functional profiles (Figure 1D; variance
266 explained = 12.9%; $R = -0.57$) driven strongly by the age of the participant at the time of collection.
267 Similarly, both amplitude and latency VEP features were strongly correlated with age, as expected
268 (18,41) That is, as infants got older, N1 amplitude became more negative (N1: $b = -0.07$, $p < .05$), corrected
269 P1 amplitude became smaller (P1: $b = -0.50$, $p < .05$), corrected N2 amplitude became smaller (N2: $b = 0.52$,
270 $p < .05$), and all latencies became shorter (N1: $b = -0.79$, $p < .05$; P1: $b = -1.21$, $p < .05$; N2: $b = -4.10$, $p < .05$)
271 (Figure 1E).

272 Microbial genes with neuroactive potential are associated with concurrently measured visual 273 development

274 To test whether microbial metabolic potential was related to early life brain activity, we performed feature
275 set enrichment analysis (FSEA) using previously-defined groups of potentially neuroactive microbial
276 genes and the concurrently measured VEP amplitude and latency features (17,5). For each gene set that
277 had at least 5 genes represented in a given comparison group, logistic regression was performed using
278 VEP features as predictors and the presence or absence of each microbial gene in the metagenome as
279 the response to determine concurrent associations (see Methods). Z statistics for in-set genes were
280 compared to all genes using a permutation test to determine significance of the associations as
281 described in Subramanian et. al., (2005) (38).

282 Of the 35 genesets assessed, 19 had sufficient representation to test, and of those, 18 were significantly
283 associated with at least one EEG feature during at least one visit within the 18-month window, after
284 correcting for false discovery rate (Benjamini-Hochberg, $q < 0.2$; Figure 2, Table S2). Microbial genes
285 involved in synthesis or degradation of molecules with neuroactive potential across all categories
286 considered (i.e., neurotransmitters, amino acid metabolism, SCFAs, other) were associated with both
287 VEP amplitudes and latencies at each visit, demonstrating widespread associations between early life gut
288 microbiome and visual cortex neurodevelopment. The number of these associations increased over time
289 (visit-1 had 6 associations, visit-2 had 24, and visit-3 had 37). To differentiate whether this cross-sectional
290 finding indicated the early microbiome (~4 months) was sparsely related to visual cortical development at
291 4 months only or more broadly at all subsequent time points, longitudinal analyses were performed
292 (results below).

293 Specifically, across the gene sets involved in neurotransmitter synthesis and degradation, glutamate
294 synthesis/degradation and GABA synthesis showed associations with all VEP features, primarily at the
295 2nd and 3rd visit (mean ages 8.6 and 14.1 months, respectively; Table S2). Gene sets involved in
296 tryptophan metabolism and associated pathways (i.e., quinolinic acid) were also strongly concurrently
297 related to VEP development. Specifically, tryptophan metabolism genes were associated with VEP
298 latencies just after each VEP component showed its greatest window of developmental change
299 (components emerge sequentially as follows: P1, N1, N2), that is, of P1 at visit-1, N1 and P1 at visit-2,
300 and N2 at visit-3.

301 Several short-chain fatty acid (SCFA)-metabolizing gene sets were also found to have multiple
302 associations with VEP features. Specifically, acetate synthesis was strongly associated with almost all
303 VEP features (Table S2). Butyrate synthesis was associated with P1 and N2 amplitudes and latencies

304 around the end of the first year of life (visits 2 and 3), when the visual cortex is most actively undergoing
305 myelination. Lastly, propionate synthesis/degradation was significantly associated with VEP latencies at
306 every visit over the 18-month window (N1 at visits 1 and 2, and both P1 and N2 at visit-3). These SCFA
307 metabolizing genes showed almost double the concurrent associations with VEP latencies than
308 amplitudes (11 associations with latencies, 6 associations with amplitudes).

309 Finally, within the remaining gene sets tested, we observed robust associations in particular between
310 menaquinone (Vitamin K2) gene sets and the VEP features over this infancy window. This is an expected
311 relationship, as vitamin K2 specifically is posited to promote healthy vision, both outside of the brain
312 through effects on the retina, and within the brain where it can protect neural circuits from oxidative stress
313 (43).

314 Notably, across significant gene set associations with VEP features, the P1 and N2 component
315 amplitudes and latencies were consistently the most sensitive to these microbial gene sets. Both P1 and
316 N2 components are known to show the most dramatic changes with development during the first year of
317 life (44) and may best reflect underlying visual learning and plasticity at this stage (Table S1).

318 Microbial metabolic potential predicts future brain development in infancy Given that differences in
319 metabolic potential of the early life microbiome may exert their effects over time, we sought to determine
320 whether microbial genes at early time points were associated with subsequent VEP development. To
321 investigate this, we performed FSEA on stool samples collected at visit-1 with visit-2 VEP (age at stool
322 collection = 3.6 ± 0.8 months, age at VEP = 8.6 ± 1.5 months) or visit-3 VEP (age at stool collection = 3.7
323 ± 0.7 months, age at VEP = 14.1 ± 1.1 months), as well as visit-2 stool samples with visit-3 VEP (age at
324 stool collection = 8.9 ± 1.5 months, age at VEP = 14.3 ± 1.0 months; Table S3) (Figure 3A).

325 All gene sets except those involved in the synthesis of 3,4-dihydroxyphenylacetic acid (DOPAC), a
326 metabolite of dopamine, that had a significant hit with concurrently measured VEP were also significantly
327 associated with at least one future VEP feature (Figure 3B, Tables 2-5). Notably, the quantity of those
328 associations increased substantially for all longitudinal comparisons compared to concurrent
329 comparisons. For example, only 6 visit-1 microbial gene sets were associated with visit-1 VEP, and each
330 of those was only associated with a single concurrently measured VEP feature. By contrast, these
331 longitudinal analyses revealed that visit-1 microbial gene sets show a much richer pattern of associations
332 with future VEP feature development. Specifically, 13 visit-1 gene sets were associated with visit-2 VEP
333 features, and 11 were associated with visit-3 VEP features, the majority (9/13 for visit-2, 8/11 for visit-3)
334 were associated with at least 2 VEP features, and nearly half (6/13 for visit-2, 5/11 for visit-3) were
335 associated with more than 2 future VEP features.

336 Longitudinally, the early microbiome (visit-1) was related to VEP features at visit-2 and visit-3 fairly evenly
337 (12/28 visit-1 microbiome associations to visit-3 VEP latencies, 15/30 associations to visit-3 amplitudes),
338 suggesting early microbiome metabolism in the first 6 months of life is associated with visual
339 neurodevelopment over the next year. Microbiome metabolism from visit-2 was associated with similar
340 numbers of visit-3 VEP features as visit-1 microbiome (17 visit-3 latency features, 18 visit-3 amplitude
341 features), suggesting continued co-development of these systems over the first postnatal year.
342 Neurotransmitters GABA and glutamate, tryptophan metabolism (tryptophan and quinolinic acid), SCFAs
343 including acetate, butyrate, and propionate, as well as menaquinone (Vitamin K2) were again all
344 significantly associated with multiple VEP features across multiple longitudinal comparisons.

345 Importantly, the nature and identity of the longitudinal associations varied over development for many
346 gene sets, indicating temporal specificity to these associations. With respect to the neurotransmitter-
347 related pathways, amongst the associations between GABA synthesis genes and future VEP features,
348 GABA genes specifically from visit-1 showed the greatest number of associations with future VEP
349 features (5/6 GABA associations) at visits 2 and 3 equally, and the majority of these associations were

350 VEP amplitudes (reflecting development of neurotransmission including excitatory/inhibitory balance). To
351 a lesser extent, glutamate metabolism genes followed a similar temporal pattern (8/13 glutamate
352 associations involved visit-1 genes) but did not relate to amplitudes or latencies differentially like GABA.
353 This pattern of results suggests early (within the first 6 postnatal months) microbiome GABA/glutamate
354 dynamics, especially GABA, are most relevant for changes to visual cortex function over the following
355 year.

356 Tryptophan-related pathway genes (responsible for generating serotonin, amongst other products) from
357 visit-1 were also responsible for the majority of associations with future VEP features (tryptophan: 6/8
358 associations; quinolinic acid: 6/9 associations). In contrast to GABA but similar to glutamate, tryptophan-
359 related gene associations were largely shorter-term associations with VEP features at the visit
360 immediately following gene set measurement (approximately 5 months later; 12/17 associations),
361 indicating dynamic co-development over the first 18 months of life. Across neurotransmitter-related gene
362 set associations (GABA, glutamate, tryptophan/serotonin), there was thus a clear pattern whereby early
363 (~4 months old) microbiome gene sets showed the largest number of associations with subsequent VEP
364 feature development.

365 SCFAs showed a different developmental pattern of associations with future VEP features. Specifically,
366 propionate and butyrate metabolism genes from both visit-1 and visit-2 showed associations with future
367 VEP features, but here the effects were almost entirely observed for VEP features at visit-3 (10/10
368 propionate and 7/8 butyrate associations). Moreover, acetate and butyrate metabolism genes were
369 doubly associated with future VEP latencies compared to amplitude features.

370 Finally, menaquinone (Vitamin K2) metabolism genes followed a similar pattern to the SCFAs in that
371 genes from visit-1 and visit-2 were largely associated with future VEP features at visit-3 (8/9
372 menaquinone associations). This indicates persistent associations of this early microbiome gene set with
373 individual differences in VEP features early in the second year of life.

374 It is possible that extrinsic factors related to development mutually influence both the gut microbiome and
375 neural development, though we additionally tested whether VEP features were associated with microbial
376 metabolism at a future visit, and found substantially fewer associations (29 total associations, compared
377 with 95 when analyzing early stool samples with future VEP). While this does not prove a causal
378 relationship, it is consistent with the hypothesis that microbial metabolism influences brain development.

379 **Discussion**

380 The past decade has seen a remarkable growth in our understanding of the relationships between the
381 developmental changes of the gut microbiome and the brain. However, a great deal of that investigation
382 has focused on adult populations or neuropsychiatric disorders, limiting the potential to explain how these
383 associations emerge during early development. Here, we address this key open question by leveraging a
384 rich longitudinal dataset over the first year of life, which is the time of greatest developmental change for
385 both the microbiome and brain given the unfolding of foundational sensory neurodevelopment. Our data
386 revealed that microbial genes involved in the metabolism of neuroactive molecules are associated with
387 concurrent and subsequent visual cortical neurodevelopment. These pathways included those for the
388 neurotransmitters GABA and glutamate, the amino acid tryptophan, and short-chain fatty acids involved
389 in myelination, including acetate and butyrate.

390 Specifically, we have shown a robust, prospective relationship between microbial genes involved in the
391 metabolism of neuroactive compounds and the development of visual cortical function as measured by
392 the VEP electrophysiological response. We found that microbial metabolism is more strongly associated
393 with future measures of the VEP than those collected concurrently. While not dispositive, this would be
394 the predicted outcome if microbial genes are causally influencing brain development. As additional

395 evidence for this interpretation, we did not observe the same rich set of associations in the converse
396 analyses examining whether VEP related to future microbiome properties. Microbial metabolism within
397 the first 6 months shows the most associations with subsequent visual neurodevelopment, suggesting
398 the early postnatal microbiome may play a particularly important role in the co-development of these
399 systems. This interpretation is also supported by prior research showing that associations of the
400 microbiome with behavioral readouts of neurocognition are stronger prospectively than concurrently (45).
401 Moreover, specific associations between gene sets and VEP features showed temporal specificity within
402 the 18-month developmental window assessed, suggesting that the impact of early microbial metabolism
403 on the brain is developmentally dependent.

404 Notably, the gene sets most highly associated with visual functional neurodevelopment over infancy are
405 for the metabolism of molecules with known links to developmental neuroplasticity (46–48). Specifically,
406 we observed associations for gene sets related to glutamate and GABA, neurotransmitters that are
407 central to regulating excitatory/inhibitory (E/I) cortical balance. Developmental changes in E/I balance
408 modulate the degree of neuroplasticity in the mammalian cortex, including regulating the start and
409 progression of critical period neuroplasticity mechanisms in the visual cortex (47,46,49,50). Our observed
410 pattern of results suggests early (within the first 6 postnatal months) microbiome GABA/glutamate
411 dynamics, especially GABA, are most relevant for changes to visual cortex function over the following
412 year. Gut production of GABA may influence cortical GABA levels via active transport from bloodstream
413 to brain (51–53). Recent evidence suggests gut-derived glutamate may also influence brain levels and
414 function (8–10) and can operate via indirect mechanisms (either transformation into GABA or via
415 regulating glutamate levels in the bloodstream that impact glutamate transfer from brain to bloodstream).

416 Tryptophan related pathway genes were also identified here that are responsible for generating serotonin
417 as well as other neuroactive molecules such as kynurenic acid (an SMDAR antagonist) (12). Both
418 serotonin and kynurenic acid are implicated in early neuroplasticity and neurotransmitter regulation, and
419 serotonin has potent effects for visual cortex plasticity in particular (54,55). While quinolinic acid is part of
420 the kynurenine pathway and is a neurotoxin that can cause neuronal dysfunction, it may also play a role
421 in glutamate uptake in the brain (56,57). Specifically, tryptophan metabolism genes were associated with
422 VEP latencies just after each VEP component showed its greatest window of developmental change
423 (components emerge sequentially as follows: P1, N1, N2), that is, of P1 at visit-1, N1 and P1 at visit-2,
424 and N2 at visit-3. This pathway may thus relate to processes stabilizing the neural circuitry (i.e.
425 downregulating neuroplasticity) underlying each VEP component, an account consistent with recently
426 observed effects of serotonin within the visual cortex in rodents (58). Importantly, nearly all of the body's
427 serotonin is produced in the gut by enterochromaffin cells, and this biosynthesis is regulated by microbes
428 (59,60), making this pathway an especially promising candidate intervention target for further research in
429 development.

430 We further found that gene sets for short-chain fatty acids important in downregulating neuroinflammation
431 and promoting myelination within the brain were robustly related to visual neurodevelopment. Myelination
432 is important for down-regulating plasticity in neural circuitry over development by stabilizing and
433 protecting circuits that have been shaped by early experience (61). Specifically, we observed
434 associations between acetate, butyrate, and propionate genes with VEP development. Acetate is a
435 critical component required for the increased lipid synthesis that happens during postnatal myelination in
436 the brain (62). Circulating butyrate also increases myelination (63), and though propionate's relation to
437 myelinating oligodendrocytes remains unclear, it is known to protect myelinating Schwann cells outside of
438 the brain from oxidative stress (64). Acetate, butyrate, and propionate are all also widely regarded as
439 neuroprotective by promoting healthy microglial development and downregulating neuroinflammation that
440 interferes with myelination (65). VEP latency features reflect myelination (50,66,67), and accordingly,
441 these SCFAs showed more associations with VEP latency features prospectively, especially VEP latency

442 features in vsit 3. This pattern of results is consistent with these SCFA roles' in myelination occurring over
443 the second half of the developmental window studied. SCFAs including acetate, butyrate, and propionate
444 can pass the blood-brain barrier to directly influence myelination-related processes within the brain.
445 Taken together, the pattern of results across GABA, glutamate, tryptophan, and SCFA gene sets
446 suggests early postnatal microbiome-derived metabolites relate to key neuroplasticity regulation
447 processes within the cortex.

448 Our study is a substantial advancement over prior work on the microbial-gut-brain axis in early life due to
449 the sequencing method, the large number of participants, the longitudinal study design, and the inclusion
450 of participants from a previously under-represented region of the world. The use of shotgun metagenomic
451 sequencing enables direct interrogation of microbial metabolic potential. Prior research primarily used
452 amplicon (16S rRNA gene) sequencing, which enables lower-resolution taxonomic identification and is
453 restricted to inferring metabolic potential based on taxonomy. Moreover, while several studies in infancy
454 have inferred gut-brain associations by linking microbiome measures to subsequent neurodevelopmental
455 measures using behavioral assessments (e.g., Bayley Scales of Infant Development), noting
456 associations with visually-mediated cognition (45), this study assessed the development of the visual
457 cortex directly using the VEP. The VEP is advantageous because features reflect largely
458 neurotransmission-related (via amplitudes) or structural (i.e., myelination, via latencies) changes over this
459 developmental window, facilitating some specificity in the observed associations. Moreover, the VEP can
460 be indexed with fidelity from birth, providing a continuous measure of visual cortical function across the
461 study age-range. Additionally, this study involved a large number of participants (194) contributing dense
462 longitudinal data, with up to three time points, all taken in the first 18 months of an infant's life. While prior
463 work focused on single time point measures of microbiome and neurodevelopment (68), longitudinal
464 associations allowed us to investigate the changing relation between gut microbial metabolism and the
465 development of visual neurocircuitry over time.

466 One limitation of this study is the fact that we are only able to observe the genomic composition of the
467 microbiome, rather than the concentration of metabolites themselves. This prevents us from determining
468 the concentration of these molecules in the gastrointestinal tract, blood, and brain, as the abundance of
469 these genes does not provide information about their activity, their interactions with other metabolic
470 pathways (including those of the host), or absorption by colonic epithelial cells. Moreover, the relationship
471 between gene abundance and molecule concentration may be counterintuitive, since the relationship
472 between degradation and synthesis of metabolites occurs both at the individual organism level and at the
473 community level. For example, genes for breaking down a molecule may be prevalent if that molecule is
474 at high concentrations, or the molecules may be rapidly degraded by other members of the community
475 the moment they are produced. Furthermore, it may be that the relation between metabolite and brain
476 development remains stable over time, but the relation between molecules and microbial selection
477 changes at different stages of life. Addressing these limitations in humans is challenging, even if looking
478 at stool metabolites, because overall exposure throughout the gastrointestinal tract is not necessarily
479 reflected in the final concentration of those molecules in stool. Therefore, metabolites from blood plasma
480 could provide more accurate systemic concentrations of molecules, but challenges remain on how to
481 interpret them in humans (69,70).

482 Given that the VEP is evolutionarily conserved in mammals and can be accurately measured during
483 development, the hypotheses generated in humans in this study are readily testable mechanistically
484 using in vivo models in future research. For example, VEP could be assessed in germ-free or defined-
485 microbiome animals (Wymore Brand et al. 2015; Kennedy, King, and Baldrige 2018) and may be
486 supplemented with specific molecules such as SCFAs, or colonized with microbial species lacking or
487 providing specific metabolic pathways. Furthermore, molecule concentrations in tissues from the gut to
488 the brain can be directly assessed in these models. Uncovering relations between microbial metabolism

489 and specific molecules may also generate hypotheses that can be confirmed in human data. This study,
490 therefore, provides a foundation for deep investigation of the link between the human gut microbiome and
491 brain development.

492 **Acknowledgments**

493 We would like to extend our thanks to all the caregivers and their infants who generously provided their
494 time and samples for this study. We are also grateful to the dedicated nurses and researchers who
495 recruited participants and collected data, ensuring the success of this project. This research was
496 supported by the Wellcome LEAP 1kD program.

497 **CRedit**

498 Conceptualization: KSB, ETM, KAD, LJGD, VKC

499 Data curation: KSB, ETM, GFB, FP, SM, MRZ, MM, DH

500 Formal analysis: KSB, ETM

501 Funding acquisition: KSB, NP, DCA, DKJ, SCRW, DA, MG, WPF, KAD, LJGD, VKC

502 Investigation: KSB, ETM, GFB, SM, MRZ, MM, DH

503 Methodology: KSB, NP, DCA, DKJ, SCRW, DA, MG, WPF, KAD, LJGD, VKC

504 Project administration: MRZ, MM, DH, LJGD, VKC

505 Software: KSB, ETM, GFB, CH, LJGD

506 Resources: SM, AS, FP, MRZ, MM, LD, CB, Khula, KAD, VKC

507 Supervision: KSB, LJGD, VKC

508 Validation: KSB, ETM

509 Visualization: KSB, ETM

510 Writing – original draft: KSB, ETM, LJGD, VKC

511 Writing – review & editing: KSB, ETM, CH, NP, KAD

512 **Author correspondence**

513 Vanja Klepac-Ceraj
514 vklepacc@wellesley.edu
515 781-283-3541
516 106 Central St
517 Wellesley, MA 02481

Laurel Gabard-Durnam
l.gabard-durnam@northeastern.edu
628 ISEC
Northeastern University
Boston, MA 02482

518 **Bibliography**

- 519 1. Rhee S H, Pothoulakis C, Mayer E A (2009): Principles and Clinical Implications of the Brain-Gut-
520 Enteric Microbiota Axis. *Nature Reviews Gastroenterology & Hepatology* 6: 306–314.
- 521 2. Collins S M, Surette M, Bercik P (2012): The Interplay between the Intestinal Microbiota and the Brain.
522 *Nature Reviews Microbiology* 10: 735–742.
- 523 3. Brett B E, Weerth C de (2019): The Microbiota–Gut–Brain Axis: A Promising Avenue to Foster Healthy
524 Developmental Outcomes. *Developmental Psychobiology* 61: 772–782.
- 525 4. Gilbert J A, Blaser M J, Caporaso J G, Jansson J K, Lynch S V, Knight R (2018): Current
526 Understanding of the Human Microbiome. *Nature Medicine* 24: 392–400.
- 527 5. Valles-Colomer M, Falony G, Darzi Y, Tigchelaar E F, Wang J, Tito R Y, *et al.* (2019): The Neuroactive
528 Potential of the Human Gut Microbiota in Quality of Life and Depression. *Nature microbiology* 4: 623–
529 632.
- 530 6. Janik R, Thomason L A M, Stanisz A M, Forsythe P, Bienenstock J, Stanisz G J (2016): Magnetic
531 Resonance Spectroscopy Reveals Oral Lactobacillus Promotion of Increases in Brain GABA, N-acetyl
532 Aspartate and Glutamate. *NeuroImage* 125: 988–995.

- 533 7. Ahmed H, Leyrolle Q, Koistinen V, Kärkkäinen O, Layé S, Delzenne N, Hanhineva K (2022):
534 Microbiota-Derived Metabolites as Drivers of Gut–Brain Communication. *Gut Microbes* 14: 2102878–
535 2102879.
- 536 8. Matsumoto M, Kibe R, Ooga T, Aiba Y, Sawaki E, Koga Y, Benno Y (2013): Cerebral Low-Molecular
537 Metabolites Influenced by Intestinal Microbiota: A Pilot Study. *Frontiers in Systems Neuroscience* 7:
538 9–10.
- 539 9. Kawase T, Nagasawa M, Ikeda H, Yasuo S, Koga Y, Furuse M (2017): Gut Microbiota of Mice
540 Putatively Modifies Amino Acid Metabolism in the Host Brain. *The British Journal of Nutrition* 117:
541 775–783.
- 542 10. Filpa V, Moro E, Protasoni M, Crema F, Frigo G, Giaroni C (2016): Role of Glutamatergic
543 Neurotransmission in the Enteric Nervous System and Brain-Gut Axis in Health and Disease.
544 *Neuropharmacology* 111: 14–33.
- 545 11. Baj A, Moro E, Bistoletti M, Orlandi V, Crema F, Giaroni C (2019): Glutamatergic Signaling Along The
546 Microbiota-Gut-Brain Axis. *International Journal of Molecular Sciences* 20: 1482–1483.
- 547 12. Agus A, Planchais J, Sokol H (2018): Gut Microbiota Regulation of Tryptophan Metabolism in Health
548 and Disease. *Cell Host & Microbe* 23: 716–724.
- 549 13. Dalile B, Van Oudenhove L, Vervliet B, Verbeke K (2019): The Role of Short-Chain Fatty Acids in
550 Microbiota–Gut–Brain Communication. *Nature Reviews Gastroenterology & Hepatology* 16: 461–
551 478.
- 552 14. Erny D, Dokalis N, Mezö C, Castoldi A, Mossad O, Staszewski O, *et al.* (2021): Microbiota-Derived
553 Acetate Enables the Metabolic Fitness of the Brain Innate Immune System during Health and
554 Disease. *Cell Metabolism* 33: 2260–2276.
- 555 15. Parker A, Fonseca S, Carding S R (2019): Gut Microbes and Metabolites as Modulators of Blood-
556 Brain Barrier Integrity and Brain Health. *Gut Microbes* 11: 135–157.
- 557 16. Aburto M R, Cryan J F (2024): Gastrointestinal and Brain Barriers: Unlocking Gates of
558 Communication across the Microbiota–Gut–Brain Axis. *Nature Reviews Gastroenterology &*
559 *Hepatology* 21: 222–247.
- 560 17. Bonham K, Bottino G F, McCann S H, Beauchemin J, Weisse E, Barry F, *et al.* (2023): Gut-Resident
561 Microorganisms and Their Genes Are Associated with Cognition and Neuroanatomy in Children.
562 *Science Advances* 9: eadi497.
- 563 18. Lippé S, Roy M-S, Perchet C, Lassonde M (2007): Electrophysiological Markers of Visuocortical
564 Development. *Cerebral Cortex* 17: 100–107.
- 565 19. Dean D C, O'Muircheartaigh J, Dirks H, Waskiewicz N, Lehman K, Walker L, *et al.* (2014): Modeling
566 Healthy Male White Matter and Myelin Development: 3 through 60 ~ Months of Age. *NeuroImage* 84:
567 742–752.
- 568 20. Ahrens A P, Hyötyläinen T, Petrone J R, Igelström K, George C D, Garrett T J, *et al.* (2024): Infant
569 Microbes and Metabolites Point to Childhood Neurodevelopmental Disorders. *Cell* 187: 1853–1873.
- 570 21. Meyer K, Lulla A, Debroy K, Shikany J M, Yaffe K, Meirelles O, Launer L J (2022): Association of the
571 Gut Microbiota With Cognitive Function in Midlife. *JAMA Network Open* 5: e2143941.
- 572 22. Callaghan B L, Fields A, Gee D G, Gabard-Durnam L, Caldera C, Humphreys K L, *et al.* (2020): Mind
573 and Gut: Associations between Mood and Gastrointestinal Distress in Children Exposed to Adversity.
574 *Development and Psychopathology* 32: 309–328.

- 575 23. Canipe L G, Sioda M, Cheatham C L (2021): Diversity of the Gut-Microbiome Related to Cognitive
576 Behavioral Outcomes in Healthy Older Adults. *Archives of Gerontology and Geriatrics* 96: 104464–
577 104465.
- 578 24. Lupori L, Cornuti S, Mazziotti R, Borghi E, Ottaviano E, Cas M D, *et al.* (2022): The Gut Microbiota of
579 Environmentally Enriched Mice Regulates Visual Cortical Plasticity. *Cell Reports* 38. [https://doi.org/](https://doi.org/10.1016/j.celrep.2021.110212)
580 10.1016/j.celrep.2021.110212
- 581 25. Deen B, Richardson H, Dilks D D, Takahashi A, Keil B, Wald L L, *et al.* (2017): Organization of High-
582 Level Visual Cortex in Human Infants. *Nature Communications* 8: 13995–13996.
- 583 26. Ellis C T, Yates T S, Skalaban L J, Bejjanki V R, Arcaro M J, Turk-Browne N B (2021): Retinotopic
584 Organization of Visual Cortex in Human Infants. *Neuron* 109: 2616–2626.
- 585 27. Kiorpes L (2015): Visual Development in Primates: Neural Mechanisms and Critical Periods.
586 *Developmental Neurobiology* 75: 1080–1090.
- 587 28. Zieff M R, Miles M, Mbale E, Eastman E, Ginnell L, Williams S C R, *et al.* (2024): Characterizing
588 Developing Executive Functions in the First 1000 Days in South Africa and Malawi: The Khula Study.
589 *Wellcome Open Research* 9: 157–158.
- 590 29. Mlandu N, McCormick S A, Davel L, Zieff M R, Bradford L, Herr D, *et al.* (2024): Evaluating a Novel
591 High-Density EEG Sensor Net Structure for Improving Inclusivity in Infants with Curly or Tightly Coiled
592 Hair. *Developmental Cognitive Neuroscience* 67: 101396–101397.
- 593 30. Monachino A D, Lopez K L, Pierce L J, Gabard-Durnam L J (2022): The HAPPE plus Event-Related
594 (HAPPE+ER) Software: A Standardized Preprocessing Pipeline for Event-Related Potential Analyses.
595 *Modeling Neural Development* 57: 101140–101141.
- 596 31. Comeau A M, Filloramo G V (2023): Preparing Multiplexed WGS/MetaG Libraries with the Illumina
597 DNA Prep Kit for the Illumina NextSeq or MiSeq. Retrieved August 14, 2024, from [https://www.](https://www.protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w)
598 [protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w](https://www.protocols.io/view/preparing-multiplexed-wgs-metag-libraries-with-the-b5z4q78w)
- 599 32. Bates D, Mächler M, Bolker B, Walker S (2015): Fitting Linear Mixed-Effects Models Using Lme4.
600 *Journal of Statistical Software* 67: 1–48.
- 601 33. Beghini F, McIver L J, Blanco-Míguez A, Dubois L, Asnicar F, Maharjan S, *et al.* (2021): Integrating
602 Taxonomic, Functional, and Strain-Level Profiling of Diverse Microbial Communities with bioBakery 3.
603 *Elife* 10. <https://doi.org/10.7554/eLife.65088>
- 604 34. Bezanson J, Edelman A, Karpinski S, Shah V B (2017): Julia: A Fresh Approach to Numerical
605 Computing. *Siam Review* 59: 65–98.
- 606 35. Bonham K, Kayisire A, Luo A, Klepac-Ceraj V (2021): Microbiome.JI and BiobakeryUtils.JI - Julia
607 Packages for Working with Microbial Community Data. *Journal of Open Source Software* 6: 3876–
608 3877.
- 609 36. Suzek B E, Huang H, McGarvey P, Mazumder R, Wu C H (2007): UniRef: Comprehensive and Non-
610 Redundant UniProt Reference Clusters. *Bioinformatics* 23: 1282–1288.
- 611 37. Kanehisa M, Goto S, Kawashima S, Okuno Y, Hattori M (2004): The KEGG Resource for Deciphering
612 the Genome. *Nucleic Acids Research* 32: D277–D280.
- 613 38. Subramanian A, Tamayo P, Mootha V K, Mukherjee S, Ebert B L, Gillette M A, *et al.* (2005): Gene Set
614 Enrichment Analysis: A Knowledge-Based Approach for Interpreting Genome-Wide Expression
615 Profiles. *Proceedings of the National Academy of Sciences* 102: 15545–15550.

- 616 39. Bonham K (2024, September 1): Klepac-Ceraj-Lab/EEGMicrobiome: Initial Submission. <https://doi.org/10.5281/zenodo.13625448>
617
- 618 40. Koenig J E, Spor A, Scalfone N, Fricker A D, Stombaugh J, Knight R, *et al.* (2011): Succession of
619 Microbial Consortia in the Developing Infant Gut Microbiome. *Proceedings of the National Academy of*
620 *Sciences of the United States of America* 4578–4585.
- 621 41. Yassour M, Vatanen T, Siljander H, Hämäläinen A-M, Härkönen T, Ryhänen S J, *et al.* (2016): Natural
622 History of the Infant Gut Microbiome and Impact of Antibiotic Treatment on Bacterial Strain Diversity
623 and Stability. *Science Translational Medicine* 8: 343–344.
- 624 42. Bäckhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, *et al.* (2015): Dynamics and
625 Stabilization of the Human Gut Microbiome during the First Year of Life. *Cell host & microbe* 17: 690–
626 703.
- 627 43. Li J, Lin J C, Wang H, Peterson J W, Furie B C, Furie B, *et al.* (2003): Novel Role of Vitamin K in
628 Preventing Oxidative Injury to Developing Oligodendrocytes and Neurons. *Journal of Neuroscience*
629 23: 5816–5826.
- 630 44. Lippe S, Kovacevic N, McIntosh R (2009): Differential Maturation of Brain Signal Complexity in the
631 Human Auditory and Visual System. *Frontiers in Human Neuroscience* 3. [https://doi.org/10.3389/](https://doi.org/10.3389/neuro.09.048.2009)
632 [neuro.09.048.2009](https://doi.org/10.3389/neuro.09.048.2009)
- 633 45. Carlson A L, Xia K, Azcarate-Peril M A, Goldman B D, Ahn M, Styner M A, *et al.* (2018): Infant Gut
634 Microbiome Associated With Cognitive~Development. *Biological Psychiatry* 83: 148–159.
- 635 46. Fagiolini M, Hensch T K (2000): Inhibitory Threshold for Critical-Period Activation in Primary Visual
636 Cortex. *Nature* 404: 183–186.
- 637 47. Hensch T K, Fagiolini M, Mataga N, Stryker M P, Baekkeskov S, Kash S F (1998): Local GABA Circuit
638 Control of Experience-Dependent Plasticity in Developing Visual Cortex. *Science* 282: 1504–1508.
- 639 48. Takesian A E, Bogart L J, Lichtman J W, Hensch T K (2018): Inhibitory Circuit Gating of Auditory
640 Critical-Period Plasticity. *Nature Neuroscience* 21: 218–227.
- 641 49. Gabard-Durnam L, McLaughlin K A (2020): Sensitive Periods in Human Development: Charting a
642 Course for the Future. *Current Opinion in Behavioral Sciences* 36: 120–128.
- 643 50. Margolis E T, Davel L, Bourke N J, Bosco C, Zieff M R, Monachino A D, *et al.* (2024): Longitudinal
644 Effects of Prenatal Alcohol Exposure on Visual Neurodevelopment over Infancy. *Developmental*
645 *Psychology* 60: 1673–1698.
- 646 51. Takanaga H, Ohtsuki S, Hosoya Ki n, Terasaki T (2001): GAT2/BGT-1 as a System Responsible for
647 the Transport of Gamma-Aminobutyric Acid at the Mouse Blood-Brain Barrier. *Journal of Cerebral*
648 *Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and*
649 *Metabolism* 21: 1232–1239.
- 650 52. Al-Sarraf H (2002): Transport of 14C- γ -aminobutyric Acid into Brain, Cerebrospinal Fluid and Choroid
651 Plexus in Neonatal and Adult Rats. *Developmental Brain Research* 139: 121–129.
- 652 53. Shyamaladevi N, Jayakumar A R, Sujatha R, Paul V, Subramanian E H (2002): Evidence That Nitric
653 Oxide Production Increases γ -Amino Butyric Acid Permeability of Blood-Brain Barrier. *Brain Research*
654 *Bulletin* 57: 231–236.
- 655 54. Vetencourt J F M, Tiraboschi E, Spolidoro M, Castrén E, Maffei L (2011): Serotonin Triggers a
656 Transient Epigenetic Mechanism That Reinstates Adult Visual Cortex Plasticity in Rats. *European*
657 *Journal of Neuroscience* 33: 49–57.

- 658 55. Gu Q, Singer W (1995): Involvement of Serotonin in Developmental Plasticity of Kitten Visual Cortex.
659 *European Journal of Neuroscience* 7: 1146–1153.
- 660 56. Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, Pedraza-Chaverrí J, Ríos C, Cruz V Pérez-de la (2013):
661 Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets. *Oxidative Medicine and Cellular*
662 *Longevity* 2013: 104024–104025.
- 663 57. Tavares R G, Tasca C I, Santos C E S, Wajner M, Souza D O, Dutra-Filho C S (2000): Quinolinic Acid
664 Inhibits Glutamate Uptake into Synaptic Vesicles from Rat Brain. *NeuroReport* 11: 249–250.
- 665 58. Hong S Z, Mesik L, Grossman C D, Cohen J Y, Lee B, Severin D, et al. (2022): Norepinephrine
666 Potentiates and Serotonin Depresses Visual Cortical Responses by Transforming Eligibility Traces.
667 *Nature Communications* 13: 3202–3203.
- 668 59. Yano J M, Yu K, Donaldson G P, Shastri G G, Ann P, Ma L, et al. (2015): Indigenous Bacteria from the
669 Gut Microbiota Regulate Host Serotonin Biosynthesis. *Cell* 161: 264–276.
- 670 60. Jameson K G, Hsiao E Y (2018): Linking the Gut Microbiota to a Brain Neurotransmitter. *Trends in*
671 *Neurosciences* 41: 413–414.
- 672 61. Takesian A E, Hensch T K (2013): Balancing Plasticity/Stability across Brain Development. *Progress*
673 *in Brain Research* 207: 3–34.
- 674 62. Madhavarao C N, Arun P, Moffett J R, Szucs S, Surendran S, Matalon R, et al. (2005): Defective N-
675 acetylaspartate Catabolism Reduces Brain Acetate Levels and Myelin Lipid Synthesis in Canavan's
676 Disease. *Proceedings of the National Academy of Sciences* 102: 5221–5226.
- 677 63. Chen T, Noto D, Hoshino Y, Mizuno M, Miyake S (2019): Butyrate Suppresses Demyelination and
678 Enhances Remyelination. *Journal of Neuroinflammation* 16: 165–166.
- 679 64. Grüter T, Mohamad N, Rilke N, Blusch A, Sgodzai M, Demir S, et al. (2023): Propionate Exerts
680 Neuroprotective and Neuroregenerative Effects in the Peripheral Nervous System. *Proceedings of the*
681 *National Academy of Sciences of the United States of America* 120. [https://doi.org/10.1073/pnas.](https://doi.org/10.1073/pnas.2216941120)
682 2216941120
- 683 65. Caetano-Silva M E, Rund L, Hutchinson N T, Woods J A, Steelman A J, Johnson R W (2023):
684 Inhibition of Inflammatory Microglia by Dietary Fiber and Short-Chain Fatty Acids. *Scientific Reports*
685 13: 2819–2820.
- 686 66. Barnikol U B, Amunts K, Dammers J, Mohlberg H, Fieseler T, Malikovic A, et al. (2006): Pattern
687 Reversal Visual Evoked Responses of V1/V2 and V5/MT as Revealed by MEG Combined with
688 Probabilistic Cytoarchitectonic Maps. *NeuroImage* 31: 86–108.
- 689 67. You Y, Klistorner A, Thie J, Graham S L (2011): Latency Delay of Visual Evoked Potential Is a Real
690 Measurement of Demyelination in a Rat Model of Optic Neuritis. *Investigative Ophthalmology & Visual*
691 *Science* 52: 6911–6918.
- 692 68. Gao W, Salzwedel A P, Carlson A L, Xia K, Azcarate-Peril M A, Styner M A, et al. (2019): Gut
693 Microbiome and Brain Functional Connectivity in Infants—a Preliminary Study Focusing on the
694 Amygdala. *Psychopharmacology* 236: 1641–1651.
- 695 69. Deng K, Xu J-j, Shen L, Zhao H, Gou W, Xu F, et al. (2023): Comparison of Fecal and Blood
696 Metabolome Reveals Inconsistent Associations of the Gut Microbiota with Cardiometabolic Diseases.
697 *Nature Communications* 14: 571–572.

698 70. Dekkers K F, Sayols-Baixeras S, Baldanzi G, Nowak C, Hammar U, Nguyen D, *et al.* (2022): An
699 Online Atlas of Human Plasma Metabolite Signatures of Gut Microbiome Composition. *Nature*
700 *Communications* 13: 5370–5371.

701 **Tables**

Table 1: Overall Demographic Information		Overall (N=194)
Mean (SD) Age at EEG Data Collection (months)		
Visit 1 (N=97)		3.7 (0.85)
Visit 2 (N=129)		8.6 (1.46)
Visit 3 (N=130)		14.1 (1.03)
Mean (SD) Age at Stool Data Collection (months)		
Visit 1 (N=119)		3.6 (0.76)
Visit 2 (N=105)		8.8 (1.43)
Visit 3 (N=91)		14.0 (1.24)
Maternal Place of Birth		
South Africa		191 (98.5%)
In the African Continent (not South Africa)		3 (1.5%)
Primary Spoken Language		
Xhosa Language		187 (96.4%)
Sotho Language		2 (1.0%)
Zulu Language		1 (0.5%)
English Language		2 (1.0%)
Ndebele Language		1 (0.5%)
Afrikaans Language		1 (0.5%)
Maternal Age at Infant Birth (years)		
Mean (SD)		29.2 (5.63)
Median [Min, Max]		29.0 [18.0, 41.0]
Missing		1 (0.5%)
Maternal Educational Attainment^a		
Completed Grade 6 (Standard 4) to Grade 7 (Standard 5)		4 (2.1%)
Completed Grade 8 (Standard 6) to Grade 11 (Standard 9) i.e., high school without matriculating		78 (40.2%)
Completed Grade 12 (Standard 10) i.e., high school		88 (45.4%)
Part of university/ college/ post-matric education		13 (6.7%)
Completed university/ college/ post-matric education		11 (5.7%)
Maternal Monthly Income^b (South African Rand/ZAR)		
Less than R1000 per month		97 (50.0%)
R1000 - R5000 per month		76 (39.2%)
R5000 - R10,000 per month		16 (8.2%)
More than R10,000 per month		0 (0%)
Unknown		5 (2.6%)
Infant Biological Sex		
Female		91 (46.9%)
Male		103 (53.1%)

^aThe South African Educational System was formerly divided into years called standards, similarly to the way the United States Educational System is divided into grades. The equivalent in terms of standards is provided in parentheses next to each mentioned grade. "University/College/Post-Matric Education" refers to tertiary or post-secondary education as defined by the World Bank.

^bAt the time of writing (1/16/24), 1 US Dollar = 18.87 South African Rand (ZAR).

747 **Table 2: Longitudinal FSEA, visit-1 stool ⇒ visit-2 VEP**

748	Gene set	Feature	Component	Enrichment	Q value
749	GABA synthesis	amplitude	P1	-0.398729884	0.080789189
750			N2	0.366103605	0.112944828
751	Glutamate synthesis	latency	N1	-0.282915658	0.04452
752			P1	0.262506611	0.080789189
753		amplitude	P1	0.231653804	0.102313043
754	Glutamate degradation	latency	P1	0.336966501	0.159815385
755			N2	0.325268237	0.180080899
756		amplitude	P1	0.3256632	0.176009302
757	Tryptophan synthesis	latency	N1	-0.221130346	0.027257143
758			P1	0.167147007	0.080789189
759			N2	0.19001832	0.048457143
760		amplitude	N2	-0.163072333	0.102313043
761	Quinolinic acid synthesis	amplitude	N1	-0.273526842	0.160915663
762	Quinolinic acid degradation	latency	P1	0.197973559	0.102313043
763			N2	0.195068231	0.111888889
764	Acetate synthesis	latency	N1	-0.219089592	0.029353846
765			P1	0.192652389	0.061153846
766			N2	0.215744459	0.0318
767		amplitude	P1	0.186013239	0.0742
768			N2	-0.196033217	0.054927273
769	Butyrate synthesis	amplitude	N1	-0.31934762	0.169849412
770	Isovaleric acid synthesis	latency	N1	0.271100718	0.122307692
771		amplitude	N1	0.241218831	0.180080899
772			P1	-0.240952289	0.160915663
773	Menaquinone synthesis	latency	N1	-0.139349027	0.159815385
774	Inositol synthesis	amplitude	N1	-0.429526827	0.180430435
775		latency	N1	-0.421912686	0.183435789
776	p-Cresol synthesis	amplitude	N1	-0.366578927	0.182593548
777			P1	0.452086746	0.101457143
778			N2	-0.516450705	0.04452
779	17-beta-Estradiol degradation	latency	N2	0.355044972	0.180080899

788 **Table 3: Longitudinal FSEA, visit-1 stool ⇒ visit-3 VEP**

Gene set	Feature	Component	Enrichment	Q value
GABA synthesis	latency	P1	0.434338693	0.04452
	amplitude	P1	0.409900164	0.0742
		N2	-0.506575916	0.02544
Glutamate synthesis	latency	N1	-0.303501108	0.029353846
	amplitude	N1	-0.234405478	0.111888889
Tryptophan synthesis	latency	N1	-0.187530614	0.04452
	amplitude	P1	-0.217612428	0.0159
Quinolinic acid degradation	latency	P1	-0.186280973	0.109392
		N2	-0.262447851	0.183435789
	amplitude	P1	-0.168943012	0.160915663
Acetate synthesis	latency	N1	-0.172876999	0.080789189
Propionate synthesis	amplitude	P1	0.358659876	0.080789189
Propionate degradation	latency	N1	-0.509754961	0.109392
		P1	0.534551664	0.088061538
	amplitude	P1	0.738806805	0
		N2	-0.666912201	0.027257143
Butyrate synthesis	latency	N1	0.337326194	0.122307692
		N2	-0.323276487	0.149852055
	amplitude	P1	0.368868764	0.101457143
Menaquinone synthesis	latency	P1	0.15826763	0.087031579
	amplitude	N1	-0.141748648	0.139740845
		P1	0.148803868	0.113186441
		N2	-0.156702017	0.102313043
Inositol synthesis	amplitude	N2	-0.453803843	0.121045161
ClpB	latency	N1	-0.283505043	0.180430435
	amplitude	P1	-0.328420633	0.112944828
		N2	0.35858587	0.080012903

827 **Table 4: Longitudinal FSEA, visit-2 stool ⇒ visit-3 VEP**

828	Gene set	Feature	Component	Enrichment	Q value
829	GABA synthesis	latency	N1	-0.376215897	0.107325
830	Glutamate synthesis	latency	N1	-0.16762197	0.160915663
831			P1	0.297968912	0.0159
832		amplitude	P1	0.23424529	0.03816
833	Glutamate degradation	latency	P1	0.317418013	0.14045
834		amplitude	N2	0.282946442	0.187555102
835	Tryptophan synthesis	amplitude	N1	-0.155489037	0.060834783
836			P1	0.186539112	0.029353846
837	Quinolinic acid synthesis	latency	N1	-0.31863828	0.061056
838			P1	0.333137823	0.043725
839		amplitude	P1	0.257761121	0.139182609
840	Acetate synthesis	latency	N1	-0.16732426	0.061056
841			P1	0.257469673	0
842			N2	-0.137377692	0.152983784
843		amplitude	P1	0.146955492	0.121045161
844	Propionate synthesis	amplitude	P1	0.299415199	0.126236364
845	Propionate degradation	latency	N1	-0.550397358	0.0742
846			N2	0.449253743	0.160915663
847		amplitude	P1	0.50881464	0.111888889
848			N2	-0.422998998	0.187555102
849	Butyrate synthesis	latency	N1	-0.331642845	0.080789189
850			P1	0.333561852	0.0742
851			N2	-0.290812478	0.122307692
852		amplitude	N2	0.306668162	0.111888889
853	Isovaleric acid synthesis	latency	P1	0.231685269	0.155652632
854		amplitude	P1	0.246936789	0.112944828
855	Menaquinone synthesis	latency	N1	0.152879564	0.121045161
856			amplitude	N1	-0.164433164
857		P1		0.201456836	0.029353846
858		N2		-0.163403497	0.112167273
859	Inositol degradation	latency	N1	-0.638125991	0.029353846
860			P1	0.532338179	0.101457143
861		amplitude	P1	0.641392999	0.029353846
862	p-Cresol synthesis	latency	P1	0.311879942	0.139740845
863			N2	-0.31528647	0.139182609
864		amplitude	N1	-0.303976467	0.165814286
865	S-Adenosylmethionine synthesis	amplitude	N1	-0.222889447	0.155652632
866			P1	0.229572468	0.13479403
867	17-beta-Estradiol degradation	amplitude	P1	0.281861389	0.187555102
868	ClpB	latency	P1	0.268785756	0.180430435

883 **Figures**

884 **Figure 1: The gut microbiome and VEP both develop over the first 18 months of life.**

885 (A) Study design; participants (N=194) were seen up to 3 times over the first 18 months of life. Stool samples and EEG data were
886 collected, generating microbial functional profiles (stool) and VEP waveforms (EEG) used in subsequent analyses. (B) Longitudinal
887 sampling of study participants; Density plots (top) for stool and EEG collection show the ages represented in each visit. The scatter
888 plot (bottom) shows individual participant visits. Dotted lines connect separate visits for the same participant. When stool and EEG
889 data were collected for the same visit (purple) but not on the same day, dot represents the median age of collection, and vertical
890 bars in blue and red represent stool and EEG collections respectively. (C) Principal coordinate analysis (PCoA) by multidimensional
891 scaling (MDS) on Bray-Curtis dissimilarity of taxonomic profiles; percent variance explained (fraction of positive eigenvalues) by
892 each of the first two axes are indicated on the x and y axes respectively. (D) PCoA of microbial functional profiles (UniRef90s). (E)
893 Average (solid lines) \pm standard deviation (dotted lines) for VEP waveforms at each visit.

894 **Figure 2: Concurrent feature set enrichment analysis of microbial neuroactive genes and VEP for three visits.** FSEA results

895 for all genesets where at least one visit had a significant hit ($q < 0.2$) with at least one VEP latency (A) or amplitude (B). Dots
896 indicate the Z-statistic from logistic regression for each gene in a gene set. Vertical bars indicate the median Z-statistic for the gene
897 set as a whole. Y-axis position for each gene set indicates visit number. Visit 1 for inositol degradation and DOPAC synthesis were
898 not tested, since there were fewer than 5 genes from those genesets present in the sample (See Methods).

899 **Figure 3: Gut microbial genes predict future VEP latencies and amplitudes.** (A) Age distributions for stool samples (left) and

900 VEP (right) for each longitudinal comparison (same individual) tested, V1 stool \rightarrow V2 VEP, V1 stool \rightarrow V3 VEP, and V2 stool \rightarrow V3
901 VEP. As in Figure 2, (B) and (C) show FSEA results for all genesets where at least one visit had a significant hit ($q < 0.2$) with at
902 least one VEP latency or amplitude respectively. Dots indicate the Z-statistic from logistic regression for each gene in a gene set.
903 Vertical bars indicate the median Z-statistic for the gene set as a whole. The Y-axis position for each gene set indicates longitudinal
904 comparison. V1 \rightarrow V2 and V1 \rightarrow 3 for inositol degradation and DOPAC synthesis were not tested, since there were fewer than 5
905 genes from those genesets present in the sample (See Methods).





